Martin was named President of Caprion Proteomics in March 2007 following the merger between Caprion Pharmaceuticals and Ecopia Biosciences (now Thallion Pharmaceuticals, Inc.). As co-founder of Caprion Pharmaceuticals and its Chief Operating Officer from 2000 to March 2007, Martin led the development and implementation of Caprion’s proteomics technology and business, as well as Caprion's business development efforts which involved the negotiation of strategic alliances with over 10 major pharmaceutical companies.
Prior to Caprion, he was successively a management consultant with McKinsey & Company, VP of Sales & Marketing at Advanced Bioconcept Ltd. and its General Manager after its acquisition by NEN Life Sciences (now Perkin-Elmer). Martin is also a member of the Board of Directors of Victhom Human Bionics Inc. (TSX: VHB), Montreal InVivo and the Atlantic Cancer Research Institute.
Martin earned his bachelor’s degree in Economics from the University of Moncton prior to completing an M.A. in Economics and Politics at Oxford University as a Rhodes Scholar.